

Application No. 10/699,882
Amtd. dated August 22, 2005
Reply to Office Action of May 9, 2005

4

Amendments to the Claims:

1. to 28. (Cancelled)

29. (Currently amended) A method of immunizing a host, which comprises: administering to the host an attenuated bacteria harbouring a vector comprising a nucleic acid molecule encoding at least one immunoprotection-inducing *Chlamydia* protein or a fragment thereof which generates a *Chlamydia* protein specific immune response and a promoter operatively coupled to said nucleic acid molecule for expression of said *Chlamydia* protein or fragment thereof by cells in cells of the host but not by said in said attenuated bacteria.

30. (Original) The method of claim 29 wherein said immunoprotection inducing *Chlamydia* protein or fragment thereof is a major outer membrane protein (MOMP) of a strain of *Chlamydia*.

31. (Original) The method of claim 30 wherein said strain of *Chlamydia* is a strain of *Chlamydia pneumoniae*.

32. (Original) The method of claim 30 wherein said strain of *Chlamydia* is a strain of *Chlamydia trachomatis*.

33. (Cancelled)

34. (Previously presented) The method of claim 29 wherein said promoter is a cytomegalovirus promoter.

35. (Previously presented) The method of claim 29 wherein said vector is a plasmid vector.

36. (Previously presented) The method of claim 35 wherein said plasmid vector is pcDNA3/MOMP as seen in Figure 5.

Application No. 10/699,882
Amtd. dated August 22, 2005
Reply to Office Action of May 9, 2005

5

8 37. (Original) The method of claim 29 wherein said attenuated bacteria is an attenuated strain of *Salmonella*.

9 38. (Original) The method of claim 37 wherein said attenuated strain of *Salmonella* is an attenuated strain of *Salmonella typhimurium*.

10 39. (Original) The method of claim 29 wherein said administration is effected to mucosal surfaces.

11 40. (Original) The method of claim 39 wherein said administration is effected by intranasal administration.